You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD4-Positive T-Lymphocytes

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Circulating Cluster of Differentiation 4 Positive 28 Null T

Not yet recruiting
  • Autoimmune Hemolytic Anemia
    • (no location specified)
    Jan 31, 2023

    Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

    Completed
    Has Results
    • Recurrent Plasma Cell Myeloma
    • Refractory Plasma Cell Myeloma
    • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
    • +3 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Aug 3, 2022

    Frequency and of Regulatory Function of Positive T Lymphocytes

    Completed
    • Allergic Asthma
    • +2 more
    • double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse
    • Nantes, Pays De La Loire, France
      Nantes University Hospital
    Sep 10, 2021

    Acute Myeloid Leukemia, EBV-Positive Neoplastic Cells Present, HLA-A*0201 Positive Cells Present Trial in Seattle (Aldesleukin,

    Terminated
    Has Results
    • Acute Myeloid Leukemia
    • +4 more
    • Aldesleukin
    • +2 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Oct 15, 2021

    Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

    Active, not recruiting
    • Platinum-Resistant Fallopian Tube Carcinoma
    • +11 more
    • Aldesleukin
    • +3 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    Jul 13, 2022

    CD4+T Lymphocytes in Primary Nephrotic Syndrome With Infection

    Recruiting
    • Nephrotic Syndrome
    • +2 more
    • The study is an observational study without intervention
    • Zhuhai, Guangdong, China
      the fifth affiliated hospital of SUN YAT-SEN university
    Nov 20, 2022

    COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive Trial in Houston (biological, drug, procedure)

    Active, not recruiting
    • COL6A3 Positive
    • +3 more
    • Aldesleukin
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 22, 2022

    Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)

    Not yet recruiting
    • Hodgkin Lymphoma
    • +2 more
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center
    Oct 13, 2023

    Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma Trial in Houston (CD30.CAR-EBVST cells)

    Recruiting
    • Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
    • Classical Hodgkin Lymphoma
    • CD30.CAR-EBVST cells
    • Houston, Texas
    • +1 more
    Jul 20, 2022

    Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Taiyuan (CEA-targeted CAR-T cells)

    Recruiting
    • Gastric Cancer
    • +6 more
    • CEA-targeted CAR-T cells
    • Taiyuan, Shanxi, China
    • +1 more
    Aug 24, 2023

    Metastatic Malignant Tumor in the Liver, Metastatic Uveal Melanoma Trial in Houston (Aldesleukin, Autologous CD8+

    Active, not recruiting
    • Metastatic Malignant Neoplasm in the Liver
    • Metastatic Uveal Melanoma
    • Aldesleukin
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 20, 2023

    Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Wuhu (CEA-targeted CAR-T cells)

    Recruiting
    • Gastric Cancer
    • +7 more
    • CEA-targeted CAR-T cells
    • Wuhu, Anhui, China
      The First Affiliated Hospital of Wannan Medical College
    Nov 9, 2023

    T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,

    Recruiting
    • T-cell Acute Lymphoblastic Leukemia
    • +3 more
    • Universal CD7-specific CAR gene-engineered T cells
    • Beijing, Beijing, China
    • +2 more
    Aug 17, 2023

    SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)

    Recruiting
    • SLE (Systemic Lupus)
    • +4 more
    • CD19 targeted CAR-T cells
    • Taiyuan, Shanxi, China
      Shanxi Bethune Hospital
    Sep 25, 2023

    CD70-positive Advanced Urologic Tumors Trial in Shanghai (Anti-CD70 CAR-T cells)

    Recruiting
    • CD70-positive Advanced Urologic Neoplasms
    • Anti-CD70 CAR-T cells
    • Shanghai, Shanghai, China
      Changhai Hospital
    Aug 11, 2023

    Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL Trial in Houston (CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T

    Recruiting
    • Non-Hodgkin's Lymphoma
    • +2 more
    • CD19.CAR-CD28Z T Cells - dose escalation 2
    • CD19.CAR-CD28Z T Cells - dose escalation 1
    • Houston, Texas
    • +1 more
    Feb 10, 2022

    Glioblastoma Multiforme of Brain Trial in Duarte (CHM-1101 CAR-T cells)

    Not yet recruiting
    • Glioblastoma Multiforme of Brain
    • CHM-1101 CAR-T cells
    • Duarte, California
      City of Hope Medical Center
    Dec 19, 2022

    Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present, Recurrent Non-Small Cell Lung Carcinoma Trial in

    Terminated
    Has Results
    • Advanced Pleural Malignant Mesothelioma
    • +10 more
    • Aldesleukin
    • +4 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Aug 16, 2021

    Germ Cell Tumor, Nonseminomatous Germ Cell Tumor Trial in Chapel Hill (ATLCAR.CD30 Cells, Cyclophosphamid, Fludarabine)

    Recruiting
    • Germ Cell Tumor
    • Nonseminomatous Germ Cell Tumor
    • ATLCAR.CD30 Cells
    • +2 more
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center at University of North Ca
    Dec 13, 2022

    Lymphoma Trial in Beijing (CD70-targeting CAR-T cells)

    Recruiting
    • Lymphoma
    • CD70-targeting CAR-T cells
    • Beijing, Biotherapeutic Department Of Chinsese PLA Gereral Hospital, China
      China
    Jul 9, 2023

    Solid Tumor, Adult Trial in Beijing (CD70-targeting CAR-T cells)

    Recruiting
    • Solid Tumor, Adult
    • CD70-targeting CAR-T cells
    • Beijing, Iotherapeutic Department Of Chinsese PLA Gereral Hospital, China
      China
    Jul 8, 2023

    Idiopathic CD4-Positive, T-Lymphocytopenia Trial run by the National Institute of Allergy and Infectious Diseases (NIAID)

    Recruiting
    • Idiopathic CD4-Positive
    • T-Lymphocytopenia
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 21, 2023

    Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus

    Not yet recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +5 more
    • CD19 specific Chimeric Antigen Receptor T Cell
    • Columbus, Ohio
      Nationwide Children's Hospital
    Mar 9, 2023

    Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia Trial in

    Suspended
    • Juvenile Myelomonocytic Leukemia
    • +27 more
    • CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
    • +2 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jan 11, 2023

    Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer Trial in Nanchang (CD70 CAR-T cells)

    Recruiting
    • Renal Cell Carcinoma
    • +4 more
    • CD70 CAR-T cells
    • Nanchang, Jiangxi, China
      The First Affiliated Hospital of Nanchang University
    Aug 23, 2023